Development of ribozymes that target stathmin, a major regulator of the mitotic spindle

Antisense and Nucleic Acid Drug Development

Volumn 11, Issue 1, 2001, Pages 41-49

  Mistry, S J ^a   Benham, C J ^a   Atweh, G F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHOPROTEIN; RIBOZYME; STATHMIN;

ARTICLE; CANCER THERAPY; CATALYSIS; DOWN REGULATION; DRUG DESIGN; DRUG INHIBITION; GENE THERAPY; LEUKEMIA CELL; MITOSIS SPINDLE; PRIORITY JOURNAL; RNA CLEAVAGE; RNA STRUCTURE;

EID: 0035093537     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729001750072119     Document Type: Article

References (35)

1. A silencer element from the α-globin gene inhibits expression of β-like genes
2. Overexpression of the stathmin gene in a subset of human breast cancer
3. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules
4. Embryonic-fetal erythroid characteristics of a human leukemic cell line
5. cdc2
6. Can hammerhead ribozymes be efficient tools to inactivate gene function?
7. Design and specificity of hammerhead ribozymes against calretinin mRNA
8. An S1 nuclease mapping method for detection of low abundance transcripts
9. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma
10. Ribozyme-mediated cleavage of acute phase serum amyloid A (ASAA) mRNA in vitro
11. Expression of the leukemia-associated gene, p18, in normal and malignant tissues: Inactivation of expression in a patient with cleaved B cell lymphoma/leukemia
12. The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation
13. Taxol and anti-stathmin therapy: Synergistic combinations that target the mitotic spindle
14. Ribozyme-mediated cancer gene therapy
15. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation
16. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells
17. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
18. Therapeutic applications of ribozymes
19. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDRI (PGY1) ribozyme
20. 2/M transition requires multisite phosphorylation of oncoprotein 18 by two distinct protein kinase systems
21. Regulated expression of p18, a major phosphoprotein of leukemic cells
22. cdc2 kinase
23. Serine 25 of oncoprotein p18 is a major cytosolic target for the mitogen-activated protein kinase
24. Oncoprotein 18 is a phosphorylation responsive regulator of microtubule dynamics
25. The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control
26. Regulation of microtubule dynamics by extracellular signals: cAMP-dependent protein kinase switches off the activity of oncoprotein 18 in intact cells
27. 2-/calmodulin-dependent kinase IV/Gr-dependent phosphorylation of oncoprotein 18
28. Role for protein phosphatases in the cell-cycle-regulated phosphorylation of stathmin
29. Spontaneous δ- to β-globin switching in K562 human leukemia cells
30. RNA folding
31. Expression of oncoprotein 18 in human leukemias and lymphomas
32. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
33. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme
34. Molecular cloning of a novel human leukemia associated gene
35. On finding all suboptimal foldings of an RNA molecule